Early reports from a trial in Chicago indicate that Gilead’s drug Remdesivir is in fact effective in treating severely ill COVID patients. That’s very encouraging but the real game changer will be if it is shown to be effective for moderately and mildly ill patients - in other words can it keep them out of the hospital in the first place. That trial should be next month and last at least thirty days. But maybe - maybe, by mid June or July we can be headed out of the woods on this virus. That’s assuming we can ramp up testing by then so we know who to treat. By the way, if you are thinking about buying Gilead stock, it’s already too late. It’s up about 15 percent in after hours trading.